top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

496.41 +11.19 (+2.31%)
Delayed Quote Updated: 11:50 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >
News headline image
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 8.53% on an annualized basis producing an average annual return of 19.73%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
News headline image
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles. 
Via The Motley Fool
News headline image
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗
The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout. 
Via MarketBeat
Topics ETFs
Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals ↗
Via Chartmill
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX): Affordable Growth with Strong Fundamentals ↗
Via Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Meets a Technical Setup for a Potential Breakout ↗
Via Chartmill
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Fits the Affordable Growth Profile With Strong Earnings and Reasonable Valuation ↗
Via Chartmill
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
Exploring some of the top bargains in a multi-trillion-dollar industry. 
Via The Motley Fool
News headline image
3 of Wall Street’s Favorite Stocks to Consider Right Now
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
2 Reasons to Like VRTX (and 1 Not So Much)
Vertex Pharmaceuticals has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $452.99. The stock also fell s... 
Via StockStory
News headline image
If I Had to Start Over With $1,000 in Stocks Today, Here's Exactly What I'd Buy ↗
These well-established companies are on track to deliver more growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks. ↗
These companies don't typically compete directly with one another, but that might change soon. 
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗
The opportunity is enormous, but uncertainty remains. 
Via The Motley Fool
News headline image
3 Market-Beating Stocks Worth Investigating
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
Via StockStory
News headline image
The Best Biotech Stocks to Buy in 2026 ↗
They have at least one thing in common: An exciting pipeline. 
Via The Motley Fool
Topics ETFs
News headline image
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? ↗
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗
The company seems to be doing everything it's supposed to be doing; the stock just isn't responding. 
Via The Motley Fool
News headline image
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
The Best Stocks to Invest $500 in Right Now ↗
The market is underestimating these companies' long-term prospects. 
Via The Motley Fool
News headline image
Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade... 
Via StockStory
News headline image
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗
Are there significant gains ahead for one (or both) of these innovative biotechs? 
Via The Motley Fool
Which S&P500 stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗
The biotech's innovative platform could pay off. 
Via The Motley Fool
News headline image
Vertex to Participate in Upcoming May Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call
Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management hi... 
Via StockStory
Topics Earnings
News headline image
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗
The market wasn't impressed by its latest quarterly update. 
Via The Motley Fool
Topics Initial Public Offering
< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page